Tandem 25
MRD testing before HSCT may offer insight into survival outcomes for patients with MDS/MPN.
Adding ruxolitinib before, during, and after HSCT to standard GVHD prophylaxis reduced the incidence of GVHD.
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.
Advertisement
Several hematologists were recognized for their contributions to the fields of HSCT and cellular therapy.
CAR22 therapy demonstrated an ORR of 100% and a complete response rate of 83% in six patients with MCL or FL.
Results from DALY II USA were presented during the oral abstract session on myeloma and lymphoma at the Tandem TCT Meetings.
Advertisement
Findings from a subgroup analysis of ZUMA-7 support early referral to axi-cel therapy.
In a prospective study patients with Fanconi anemia were matched to healthy controls and underwent carotid artery ultrasound.
Patient-reported response is associated with overall response, total symptom score response, and failure-free survival.
Real-world data suggest that treatment with either axi-cel or liso-cel provides potential to sustain disease-free survival.
Coverage of the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.